Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EPS (Weighted Average and Diluted) (2016 - 2025)

Zevra Therapeutics' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at $0.19 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 127.54% year-over-year to $0.19; the TTM value through Dec 2025 reached $0.7, up 138.67%, while the annual FY2025 figure was $1.35, 159.21% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.19 in Q4 2025 per ZVRA's latest filing, up from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.21 in Q2 2025 to a low of -$2.49 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.34, with a median of -$0.23 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 290.48% in 2021, then skyrocketed 352.08% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.05 in 2021, then tumbled by 1480.0% to -$0.69 in 2024, then surged by 127.54% to $0.19 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's EPS (Weighted Average and Diluted) are $0.19 (Q4 2025), -$0.01 (Q3 2025), and $1.21 (Q2 2025).